Free Trial
→ Trump Just Named His Secret AI Project. It's Called 'Golden Dawn.' (From InvestorPlace) (Ad)tc pixel Free HVO Stock Alerts

hVIVO (HVO) Competitors

hVIVO logo
GBX 7.50 +0.05 (+0.67%)
As of 05/15/2026 12:39 PM Eastern
Compare

HVO vs. BTG, ARIX, CIR, TILS, and VSN

Should you buy hVIVO stock or one of its competitors? MarketBeat compares hVIVO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with hVIVO include BTG (BTG), Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), and Verseon (VSN). These companies are all part of the "biotechnology" industry.

How does hVIVO compare to BTG?

BTG (LON:BTG) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

BTG presently has a consensus price target of GBX 160, suggesting a potential upside of 36.17%. hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 100.00%. Given hVIVO's higher probable upside, analysts clearly believe hVIVO is more favorable than BTG.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BTG
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

hVIVO has lower revenue, but higher earnings than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£159.40M1.19N/A£6.0019.58
hVIVO£46.77M1.10£17.84M-£0.87N/A

19.3% of BTG shares are held by institutional investors. Comparatively, 10.2% of hVIVO shares are held by institutional investors. 19.8% of BTG shares are held by company insiders. Comparatively, 5.2% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BTG pays an annual dividend of GBX 4.30 per share and has a dividend yield of 3.7%. hVIVO pays an annual dividend of GBX 0.20 per share and has a dividend yield of 2.7%. BTG pays out 71.7% of its earnings in the form of a dividend. hVIVO pays out -23.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
BTGN/A N/A N/A
hVIVO -12.48%-14.65%11.97%

In the previous week, BTG and BTG both had 3 articles in the media. hVIVO's average media sentiment score of 0.07 beat BTG's score of -0.28 indicating that hVIVO is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BTG
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
hVIVO
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BTG beats hVIVO on 10 of the 15 factors compared between the two stocks.

How does hVIVO compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

In the previous week, hVIVO had 3 more articles in the media than Arix Bioscience. MarketBeat recorded 3 mentions for hVIVO and 0 mentions for Arix Bioscience. hVIVO's average media sentiment score of 0.07 beat Arix Bioscience's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company Overall Sentiment
Arix Bioscience Neutral
hVIVO Neutral

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arix Bioscience£14.16M0.00£14.96M£0.11N/A
hVIVO£46.77M1.10£17.84M-£0.87N/A

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 100.00%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Arix Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arix Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
Arix Bioscience105.64% 6.41% 2.18%
hVIVO -12.48%-14.65%11.97%

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 10.2% of hVIVO shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by insiders. Comparatively, 5.2% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arix Bioscience has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.685, indicating that its stock price is 69% more volatile than the broader market.

Summary

hVIVO beats Arix Bioscience on 9 of the 15 factors compared between the two stocks.

How does hVIVO compare to Circassia Group?

hVIVO (LON:HVO) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

10.2% of hVIVO shares are held by institutional investors. 5.2% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 100.00%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts plainly believe hVIVO is more favorable than Circassia Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Circassia Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Circassia Group has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Circassia Group's return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Circassia Group N/A N/A N/A

In the previous week, hVIVO had 3 more articles in the media than Circassia Group. MarketBeat recorded 3 mentions for hVIVO and 0 mentions for Circassia Group. hVIVO's average media sentiment score of 0.07 beat Circassia Group's score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company Overall Sentiment
hVIVO Neutral
Circassia Group Neutral

hVIVO has higher revenue and earnings than Circassia Group. hVIVO is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M1.10£17.84M-£0.87N/A
Circassia Group£27.90M0.00N/A£0.01N/A

Summary

hVIVO beats Circassia Group on 9 of the 13 factors compared between the two stocks.

How does hVIVO compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

hVIVO has a consensus target price of GBX 15, suggesting a potential upside of 100.00%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tiziana Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Tiziana Life Sciences has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Tiziana Life Sciences' return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
hVIVO -12.48%-14.65%11.97%

10.2% of hVIVO shares are held by institutional investors. 5.2% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

hVIVO has higher revenue and earnings than Tiziana Life Sciences. hVIVO is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
hVIVO£46.77M1.10£17.84M-£0.87N/A

In the previous week, hVIVO had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for hVIVO and 1 mentions for Tiziana Life Sciences. hVIVO's average media sentiment score of 0.07 beat Tiziana Life Sciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tiziana Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
hVIVO
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

hVIVO beats Tiziana Life Sciences on 10 of the 13 factors compared between the two stocks.

How does hVIVO compare to Verseon?

hVIVO (LON:HVO) and Verseon (LON:VSN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Verseon has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Verseon's return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Verseon N/A N/A N/A

10.2% of hVIVO shares are owned by institutional investors. 5.2% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 100.00%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts plainly believe hVIVO is more favorable than Verseon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Verseon
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

hVIVO has higher revenue and earnings than Verseon. hVIVO is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M1.10£17.84M-£0.87N/A
VerseonN/AN/AN/A-£14.30N/A

In the previous week, hVIVO had 3 more articles in the media than Verseon. MarketBeat recorded 3 mentions for hVIVO and 0 mentions for Verseon. hVIVO's average media sentiment score of 0.07 beat Verseon's score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company Overall Sentiment
hVIVO Neutral
Verseon Neutral

Summary

hVIVO beats Verseon on 10 of the 13 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HVO vs. The Competition

Export
MetrichVIVOBiotechnology IndustryMedical SectorLON Exchange
Market Cap£51.63M£467.15M£6.33B£2.74B
Dividend Yield2.68%3.86%2.80%6.07%
P/E Ratio-8.623.8820.29365.91
Price / Sales1.107,763.50548.2688,016.94
Price / Cash4.9413.1343.0427.89
Price / Book1.3584.219.837.74
Net Income£17.84M-£96.07M£3.56B£5.89B
7 Day Performance-1.32%0.89%0.25%0.25%
1 Month Performance-19.87%0.44%-1.30%1.56%
1 Year Performance-58.33%68.68%33.61%85.82%

hVIVO Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HVO
hVIVO
2.1481 of 5 stars		GBX 7.50
+0.7%		GBX 15
+100.0%		-58.7%£51.63M£46.77MN/AN/A
BTG
BTG
3.7256 of 5 stars		GBX 119
-0.8%		GBX 160
+34.5%		N/A£191.65M£159.40M19.834,690
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HVO) was last updated on 5/16/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Secret behind near perfectly timed stock trades…?
After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...
Traders Agency | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The gold strategy that works whether prices rise or fall
Former $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way ...
Brownstone Research | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel